UK Sovereign AI Fund Near Deal to Invest in Drug Discovery Startup Potential Sciences

UK's £500m AI fund targets drug discovery startup Potential Sciences. Government announces first investments and supercomputing access for biotech firms.

Editorial Desk

September 18, 2026 One Min Read

POLICY WIRE — London, United Kingdom — The UK government is nearing a deal to invest in Potential Sciences, a biotech firm focused on using artificial intelligence to speed up drug development, as part of its broader £500 million Sovereign AI initiative.

The Sovereign AI fund, launched earlier this year, aims to support promising AI-driven startups across multiple sectors, including healthcare and computing. Potential Sciences has emerged as one of the key beneficiaries, with officials confirming that the fund is in advanced discussions to secure an equity stake in the company.

📄 POLICY WIRE WHITEPAPER PUBLISHED: PAKISTAN’S NATIONAL SECURITY POLICY PRIORITIES

👉 READ BY CLICKING HERE

In addition to the potential investment in Potential Sciences, the government has already committed to funding other AI-focused ventures. This includes an equity stake in Callosum, an AI infrastructure startup, and providing supercomputing resources to six British companies working on drug discovery, machine learning, and bioengineering projects.

Reporting by Policy-Wire (PW)

Author

Editorial Desk

Policy Wire is your go-to editorial hub for insightful perspectives and informed analysis on pressing policy issues, both regionally and globally. Over the years, Policy Wire has collaborated with leading international news agencies—including AFP, AP, Reuters, and others—to provide fact-based reporting and nuanced commentary. With a commitment to clarity and credibility, we aim to bridge the gap between complex policy debates and public understanding, ensuring that our readers stay informed on the issues shaping the world today.